The distribution pattern regarding occurrence of bacterial vaginosis is 18.8 % in celibate women, 25 % in pregnant women and 31.7 % in women who have ever been pregnant is considered as per the research findings of Center for Disease Control and Prevention. The risk factors associated with the disease etiology of bacterial vaginosis is pelvic inflammatory disease, preterm delivery of infants, urinary tract infection and sexually transmitted diseases (STD). The product pipeline in phase 3 for treatment of bacterial vaginosis are Metronidazole oral tablets 500mg - 1% SPL7013 Gel, GDC-229, Clindamycin 100mg and Ketoconazole 400mg and Association of metronidazole; nystatin and dexamethasone.
Oral route comprises of Metronidazole, Tinidazole, clindamycin and Secnidazole. The topical route includes Metronidazole, Clindamycin and normal pH restoration gels. The normal pH restoration gels is further sub segmented as Canesbalance and VivaGel®. Recent trends prevailing in the bacterial vaginosis drugs is understood by the inclusion of market size and forecast in the scope of the report.
The competitive landscape and attractive investment proposition gives clear idea that the first line treatment drugs employed for the treatment of bacterial vaginosis and the product pipeline of key manufacturers engaged in the bacterial vaginosis treatment industry. Collaborative partnership between the key players to promote recently approved drugs are mentioned in the company profiles considered for bacterial vaginosis drugs market. The major players in global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics.
Bacterial vaginosis is the most common type of vaginal infection caused due to the pH imbalance in the vaginal environment which is triggered because of imbalance between good microflora Lactobacillus species with the bad microflora Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature with the symptoms recurring with few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations either oral or topical that are efficient in eliminating the colonization of Gardnerella vaginalis. Currently the antibiotics treatment is the preferred treatment regimen for bacterial vaginalis employing drugs such as metronidazole, clindamycin and Tinidazole. Broad spectrum antimicrobial activity e.g. secnidazole (Solosec) and immediate symptomatic relief makes antibiotic treatment the largest revenue grosser. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of good bacteria Lactobacillus species. Normal pH restoration gels e.g. Canesbalance (Bayer AG), VivaGel® (Starpharma Holdings) will have an impressive growth in the near future as it address the key problem of microflora imbalance in vaginal environment and relatively has no side effects in comparison to the antibiotics. The prominent players in bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited and Symbiomix Therapeutics.
Center for Disease Control and Prevention 2019 statistics has reported the prevalence of bacterial vaginosis in the North American women population to be around 84 % with no symptoms. The rising prevalence in the African American and Hispanic women has resulted the need for effective dosage regimen to give immediate relief. Domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drugs market. European market is driven by rising prevalence of bacterial vaginosis due to increase in the lifetime number of sexual partners, recent influx of North African refugees with previous history of bacterial vaginosis has increased treatment burden to the European healthcare segment. Asia Pacific will enjoy a superlative growth in the bacterial vaginosis drugs market due to huge revenue generated by the generic antibiotic drugs market, poor socioeconomic conditions and lack of awareness regarding personal hygiene adds to the growth of Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaign regarding self hygiene by healthcare agencies such as World Health Organization and Red Cross will proliferate the bacterial vaginosis drugs market in Latin America and Middle East and Africa.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Oral route comprises of Metronidazole, Tinidazole, clindamycin and Secnidazole. The topical route includes Metronidazole, Clindamycin and normal pH restoration gels. The normal pH restoration gels is further sub segmented as Canesbalance and VivaGel®. Recent trends prevailing in the bacterial vaginosis drugs is understood by the inclusion of market size and forecast in the scope of the report.
The competitive landscape and attractive investment proposition gives clear idea that the first line treatment drugs employed for the treatment of bacterial vaginosis and the product pipeline of key manufacturers engaged in the bacterial vaginosis treatment industry. Collaborative partnership between the key players to promote recently approved drugs are mentioned in the company profiles considered for bacterial vaginosis drugs market. The major players in global bacterial vaginosis drugs market are Sanofi Aventis, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics.
Bacterial vaginosis is the most common type of vaginal infection caused due to the pH imbalance in the vaginal environment which is triggered because of imbalance between good microflora Lactobacillus species with the bad microflora Gardnerella vaginalis. The clinical manifestation of bacterial vaginosis is asymptomatic in nature with the symptoms recurring with few days of earlier treatment with antibiotics. The treatment regimen is designed with drug formulations either oral or topical that are efficient in eliminating the colonization of Gardnerella vaginalis. Currently the antibiotics treatment is the preferred treatment regimen for bacterial vaginalis employing drugs such as metronidazole, clindamycin and Tinidazole. Broad spectrum antimicrobial activity e.g. secnidazole (Solosec) and immediate symptomatic relief makes antibiotic treatment the largest revenue grosser. Metronidazole is considered more beneficial than clindamycin for the treatment of bacterial vaginosis as it is safe during pregnancy and does not eliminate the colonization of good bacteria Lactobacillus species. Normal pH restoration gels e.g. Canesbalance (Bayer AG), VivaGel® (Starpharma Holdings) will have an impressive growth in the near future as it address the key problem of microflora imbalance in vaginal environment and relatively has no side effects in comparison to the antibiotics. The prominent players in bacterial vaginosis drugs market are Abbott Laboratories, Inc., Bayer AG, Mylan N.V., Novartis AG, Pfizer, Inc., Perrigo Company Plc, Sun Pharmaceutical Industries Ltd., Sanofi Aventis, Starpharma Holdings Limited and Symbiomix Therapeutics.
Center for Disease Control and Prevention 2019 statistics has reported the prevalence of bacterial vaginosis in the North American women population to be around 84 % with no symptoms. The rising prevalence in the African American and Hispanic women has resulted the need for effective dosage regimen to give immediate relief. Domicile of key pharmaceutical industries engaged in the production and sale of antibiotics contributes to the dominance of North America in the bacterial vaginosis drugs market. European market is driven by rising prevalence of bacterial vaginosis due to increase in the lifetime number of sexual partners, recent influx of North African refugees with previous history of bacterial vaginosis has increased treatment burden to the European healthcare segment. Asia Pacific will enjoy a superlative growth in the bacterial vaginosis drugs market due to huge revenue generated by the generic antibiotic drugs market, poor socioeconomic conditions and lack of awareness regarding personal hygiene adds to the growth of Asia Pacific bacterial vaginosis drug market. Increasing disposable income and health awareness campaign regarding self hygiene by healthcare agencies such as World Health Organization and Red Cross will proliferate the bacterial vaginosis drugs market in Latin America and Middle East and Africa.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bacterial Vaginosis Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Bacterial Vaginosis Drugs market and their expected impact during the forecast period.
Market Segmentation
Route of Administration
- Oral Route
- Metronidazole
- Tinidazole
- Clindamycin
- Secnidazole
- Topical Route
- Metronidazole
- Clindamycin
- Normal pH Restoration Gels
- VivaGel®
- Canesbalance
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Bacterial Vaginosis Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Bacterial Vaginosis Drugs market?
- Which is the largest regional market for Bacterial Vaginosis Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Bacterial Vaginosis Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Bacterial Vaginosis Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Bacterial Vaginosis Drugs Market
2.2. Global Bacterial Vaginosis Drugs Market, By Route of Administration, 2021 (US$ Million)
2.3. Global Bacterial Vaginosis Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Bacterial Vaginosis Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Bacterial Vaginosis Drugs Market Vendors
3.2. Strategies Adopted by Bacterial Vaginosis Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Bacterial Vaginosis Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Bacterial Vaginosis Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Oral Route
5.3.1.1. Metronidazole
5.3.1.2. Tinidazole
5.3.1.3. Clindamycin
5.3.1.4. Secnidazole
5.3.2. Topical Route
5.3.2.1. Metronidazole
5.3.2.2. Clindamycin
5.3.2.3. Normal pH Restoration Gels
5.3.2.3.1. VivaGel®
5.3.2.3.2. Canesbalance
6. North America Bacterial Vaginosis Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
6.3.Bacterial Vaginosis Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7. UK and European Union Bacterial Vaginosis Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.Bacterial Vaginosis Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8. Asia Pacific Bacterial Vaginosis Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.Bacterial Vaginosis Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
9. Latin America Bacterial Vaginosis Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
9.3.Bacterial Vaginosis Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
10. Middle East and Africa Bacterial Vaginosis Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
10.3.Bacterial Vaginosis Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Bacterial Vaginosis Drugs Market: By Route of Administration, 2020-2030, USD (Million)
11. Company Profile
11.1. Abbott Laboratories, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bayer AG
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Mylan N.V.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Novartis AG
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Pfizer, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Perrigo Company Plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Sun Pharmaceutical Industries Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Sanofi Aventis
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Starpharma Holdings Limited
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Symbiomix Therapeutics
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Bacterial Vaginosis Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Bacterial Vaginosis Drugs Market: Quality Assurance
Figure 5 Global Bacterial Vaginosis Drugs Market, By Route of Administration, 2021
Figure 6 Global Bacterial Vaginosis Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Bacterial Vaginosis Drugs Market, 2021
Figure 8 Market Positioning of Key Bacterial Vaginosis Drugs Market Players, 2021
Figure 9 Global Bacterial Vaginosis Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Bacterial Vaginosis Drugs Market, By Route of Administration, 2021 Vs 2030, %
Figure 11 U.S. Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 2 Global Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 3 Global Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 4 Global Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 5 North America Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 6 North America Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 7 North America Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 8 North America Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 9 U.S. Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 10 U.S. Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 11 U.S. Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 12 U.S. Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 13 Canada Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 14 Canada Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 15 Canada Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 16 Canada Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 17 Rest of North America Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 18 Rest of North America Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 19 Rest of North America Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 20 Rest of North America Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 21 UK and European Union Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 22 UK and European Union Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 23 UK and European Union Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 24 UK and European Union Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 25 UK Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 26 UK Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 27 UK Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 28 UK Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 29 Germany Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 30 Germany Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 31 Germany Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 32 Germany Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 33 Spain Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 34 Spain Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 35 Spain Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 36 Spain Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 37 Italy Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 38 Italy Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 39 Italy Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 40 Italy Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 41 France Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 42 France Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 43 France Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 44 France Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 45 Rest of Europe Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 46 Rest of Europe Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 47 Rest of Europe Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 48 Rest of Europe Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 49 Asia Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 50 Asia Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 51 Asia Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 52 Asia Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 53 China Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 54 China Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 55 China Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 56 China Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 57 Japan Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 58 Japan Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 59 Japan Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 60 Japan Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 61 India Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 62 India Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 63 India Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 64 India Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 65 Australia Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 66 Australia Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 67 Australia Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 68 Australia Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 69 South Korea Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 70 South Korea Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 71 South Korea Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 72 South Korea Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 73 Latin America Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 74 Latin America Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 75 Latin America Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 76 Latin America Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 77 Brazil Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 78 Brazil Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 79 Brazil Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 80 Brazil Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 81 Mexico Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 82 Mexico Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 83 Mexico Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 84 Mexico Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 85 Rest of Latin America Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 86 Rest of Latin America Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 87 Rest of Latin America Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 88 Rest of Latin America Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 89 Middle East and Africa Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 90 Middle East and Africa Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 91 Middle East and Africa Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 92 Middle East and Africa Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 93 GCC Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 94 GCC Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 95 GCC Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 96 GCC Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 97 Africa Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 98 Africa Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 99 Africa Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 100 Africa Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Table 101 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market By Route of Administration, 2020-2030, USD (Million)
Table 102 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market By Oral Route, 2020-2030, USD (Million)
Table 103 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market By Topical Route, 2020-2030, USD (Million)
Table 104 Rest of Middle East and Africa Bacterial Vaginosis Drugs Market By Normal pH Restoration Gels, 2020-2030, USD (Million)
Companies Mentioned
- Abbott Laboratories Inc.
- Bayer AG
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Perrigo Company Plc
- Sun Pharmaceutical Industries Ltd.
- Sanofi Aventis
- Starpharma Holdings Limited
- Symbiomix Therapeutics
